Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concerns most common reason at 52%. For booster, lack of recommendation from physician biggest factor at 39%. @rheumnow #ACR22 Abstr#0083 https://t.co/ISdTmOjIWs https://t.co/Qr47Or2a6v

• COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Pract…

Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving improved communication @rheumnow #ACR22 Abstr#0063 https://t.co/sFU1FzLUfB https://t.co/9AIOijpI0j

• Implementability of a SLE Medication Adherence Intervention - ACR Meeting Abstr…

#abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0

This might be the greatest honor of my career - thanks for including me @ACRheum!! Serious question and I’m not sure I want to know the answer Did anyone know the answer? Would be embarrassing 😂🤣😅😳 #ACR22 #KnowledgeBowl #RheumPix @RheumNow https://t.co/GhjXUgCgye

Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (after PVL) and missed diagnosis key areas for improvement. @rheumnow #ACR22 Abstr#0476 https://t.co/CYBHm8CCBv https://t.co/jIvouncdxw

• Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High -…

Don't repeat the ENA test! Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab), 89% neg. 13.4% had ENA test repeated. 96% stable results w/o change Conclusion: ENA results rarely change or yield new diagnosis of AARD #ACR22 @rheumnow abst#0725

What's the best tx strategy for SLE-induced severe thrombocytopenia? This 10-yr retro study by Dr. Cime-Ake et al. showed that RTX provided longer relapse-free survival (vs. CYC, p=0.040). No difference between IV or oral GCs and AZA or MMF. #ACR22 @RheumNow ABST#368 https://t.co/nzXZMY09jx

Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-term tx including w/ dose adjustments. Abs 0138 #ACR22 @RheumNow https://t.co/ornfXVIw49 https://t.co/eHTIIEhE37

• Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment - …

Khursheed @LatikaGupta_ et al. Gender gap in rheumatology leadership. Improvements over time in ACR and some APLAR countries, but remains hugely imbalanced @rheumnow #ACR22 Abstr#0085 https://t.co/gw4HYaRlIY https://t.co/xueC3cfqyu

• Closing the Gender Gap in Global Rheumatology Leadership- Are We There Yet? - A…

Should you repeat the dsDNA? SMART-SLE study >3400 SLE pts, > 37,582 visits. Pts with fluctuating + results or persistently + had higher rates of SLE flares HR 1.56 (95% CI 1.3-1.87, p< 0.001). Inc or Dec dsDNA Ab > 2X from last visit can predict flares @rheumnow #ACR22 abst#0327

❤️ Beta Blockers in LV-GCA 📚65 pts LV-GCA 💊 15(23%) on BB, 50(73%) not 🩻 new aortic dilatation on serial imaging in 15 (23%) - ALL in those NOT on beta blocker 💔 More studies needed, but supportive initial data 🔥 @RheumNow #ACR22 Abst#0477

#abs0127  #acr22 @rheumnow 59 adults pts from SAPHO-CNO Study (SCS) reported high scores (0.8 or >SD) for pain interference& fatigue domains vs general population. ⬇️ score on PROMIS physical function; 72.9% of subjects had a T-score < 45. https://t.co/5QfwlB98wV

#ACR22 Abstr#0769 In patients on DMARDs who didnt seroconvert after primary mRNA COVID vac, is switching to vector or booster with mRNA more effective? An RCT (N=46) showed more pts receiving booster mRNA seroconverted (63%) vs vector (18%). Tcell response was similar @RheumNow https://t.co/5GTsdhNUQZ

Barajas-Ochoa et al. Gender representation in editorial boards of rheum journals. Only 28% women editors overall. Clear discrepancies between journals. Well done @ACR_Journals ! @rheumnow #ACR22 Abstr#104 https://t.co/dpElAUSEuS https://t.co/rDAG6HwNf4

• Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumat…

Neural networks help distinguish between inflammatory arthritis, RA vs PsA, based on MRI inflammatory patterns, focusing on regions of clinical relevance. Fascinating use of tech that needs to be further evaluated clinically. Abs 0242 #ACR22 @RheumNow https://t.co/EMJZkFaMwu https://t.co/hNf70PaZX6

• Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthriti…